CRISPR Therapeutics AG (CRSP)
After hours:
- Zacks
CRISPR Therapeutics AG (CRSP) Ascends But Remains Behind Market: Some Facts to Note
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.91, moving +0.34% from the previous trading session.
- Reuters
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday. Mammoth's CRISPR-based gene editing platform and Regeneron's delivery technologies will be used to create disease-modifying medicines that can be delivered to tissues beyond the liver. CRISPR, discovered by Jennifer Doudna and CRISPR Therapeutics co-founder Emmanuelle Charpentier, uses molecular "scissors" to trim faulty parts of genes that can then be disabled or replaced with new strands of normal DNA.
- Zacks
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $55.02, representing a -0.05% change from its previous close.
